Lung tumor growth is stimulated in IFN-γ-/- mice and inhibited in IL,-4Rα-/- mice

Anticancer Research

Volumn 29, Issue 12, 2009, Pages 5095-5101

  Redente, Elizabeth F ^a   Dwyer Nield, Lori D ^a   Barrett, Bradley S ^a   Riches, David W H ^b   Malkinson, Alvin M ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

Author keywords

Activation state; Cytokines; Lung cancer; Macrophages

Indexed keywords

INTERLEUKIN 4 RECEPTOR ALPHA; URETHAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL ACTIVATION; CELL INFILTRATION; LUNG TUMOR; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME;

ANIMALS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNITY, INNATE; IMMUNOENZYME TECHNIQUES; INTERFERON-GAMMA; LUNG NEOPLASMS; MACROPHAGE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; RECEPTORS, CELL SURFACE;

EID: 75149125589     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
2. Johnson SK, Kerr KM, Chapman AD, Kennedy MM, King G, Cockburn JS and Jeffrey RR: Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 27: 27-35, 2000.
3. Koukourakis MI, Giatromanolaki A, Kakolyris S, O'Byrne KJ, Apostolikas N, Skarlatos J, Gatter KC and Harris AL: Different patterns of stromal and cancer cell thymidine Phosphorylase reactivity in non-small cell lung cancer: impact on tumour neoangiogenesis and survival. Br J Cancer 77: 1696-1703, 1998.
4. Takanami I, Takeuchi K and Kodaira S: Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology 57: 138-142, 1999.
5. Bauer AK, Dwyer-Nield LD, Keil K, Koski K and Malkinson AM: Butylated hydroxytoluene (BHT) induction of pulmonary inflammation: a role in tumor promotion. Exp Lung Res 27: 197-216, 2001.
6. Mills CD, Kincaid K, Alt JM, Heilman MJ and Hill AM: M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 164: 6166-6173, 2000.
7. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK and Suttles J: Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 175: 342-349, 2005.
8. Kotowicz K, Callard RE, Friedrich K, Matthews DJ and Klein N: Biological activity of IL-4 and IL-13 on human endothelial cells: functional evidence that both cytokines act through the same receptor. Int Immunol 8: 1915-1925, 1996.
9. Gordon S: Alternative activation of macrophages. Nat Rev Immunol 3: 23-35, 2003.
10. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A and Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 677-686, 2004.
11. Montaner LJ, da Silva RP, Sun J, Sutterwala S, Hollinshead M, Vaux D and Gordon S: Type 1 and type 2 cytokine regulation of macrophage endocytosis: differential activation by IL-4/IL-13 as opposed to IFN-gamma or IL-10. J Immunol 162: 4606-4613, 1999.
12. Munder M, Eichmann K, Moran JM, Centeno F, Soler G and Modolell M: Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol 163: 3771-3777, 1999.
13. Nair MG, Cochrane DW and Allen JE: Macrophages in chronic type 2 inflammation have a novel phenotype characterized by the abundant expression of Ym1 and Fizz1 that can be partly replicated in vitro. Immunol Lett 85: 173-180, 2003.
14. Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H, Uyemura K, Modlin R, Wollman J and Dubinett SM: Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 55: 3847-3853, 1995.
15. Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, Dolman C, Markowitz D, Wu W, Liu C, Reisfeld RA and Xiang R: Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 116: 2132-2141, 2006.
16. Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Pluddemann A, Charles K, Gordon S and Balkwill FR: Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol 176: 5023-5032, 2006.
17. Robinson-Smith TM, Isaacsohn I, Mercer CA, Zhou M, Van RN, Husseinzadeh N, Farland-Mancini MM and Drew AF: Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res 67: 5708-5716, 2007.
18. Redente EF, Orlicky DJ, Bouchard RJ and Malkinson AM: Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice. Am J Pathol 170: 693-708, 2007.
19. Malkinson AM and Beer DS: Major effect on susceptibility to urethan-induced pulmonary adenoma by a single gene in BALB/cBy mice. J Natl Cancer Inst 70: 931-936, 1983.
20. O'Donnell EP, Zerbe LK, Dwyer-Nield LD, Kisley LR and Malkinson AM: Quantitative analysis of early chemically-induced pulmonary lesions in mice of varying susceptibilities to lung tumorigenesis. Cancer Lett 241: 197-202, 2006.
21. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ and Schreiber RD: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111, 2001.
22. Kaplan DH, Shankaran V, Dighe AS, Stocken E, Aguet M, Old LJ and Schreiber RD: Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95: 7556-7561, 1998.
23. Clausen BE, Burkhardt C, Reith W, Renkawitz R and Forster I: Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 8: 265-277, 1999.
24. Herbert DR, Holscher C, Mohrs M, Arendse B, Schwegmann A, Radwanska M, Leeto M, Kirsch R, Hall P, Mossmann H, Claussen B, Forster I and Brombacher F: Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. Immunity 20: 623-635, 2004.
25. Radwanska M, Cutler AJ, Hoving JC, Magez S, Holscher C, Bohms A, Arendse B, Kirsch R, Hunig T, Alexander J, Kaye P and Brombacher F: Deletion of IL-4Ralpha on CD4 T-cells renders BALB/c mice resistant to Leishmania major infection. PLoS Pathog 3: e68, 2007.
26. Sinha P, Clements VK and Ostrand-Rosenberg S: Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 174: 636-645, 2005.
27. Dinapoli MR, Calderon CL and Lopez DM: The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduced expression of the inducible nitric oxide synthase gene. J Exp Med 183: 1323-1329, 1996.